CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Adorbs Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Adorbs Inc
36 Fourth Ave. N
Phone: (516) 544-2812p:516 544-2812 YORKTON, SK  S3N 2V7  Canada Ticker: ADOBADOB
On 5/3/2024, the Securities and Exchange Commission (SEC) charged BF Borgers CPA PC and its owner, Benjamin F. Borgers, with significant violations of Public Company Accounting Oversight Board (PCAOB) standards across more than 1,500 SEC filings from January 2021 to June 2023. The charges included falsely representing compliance with PCAOB standards to clients, fabricating audit documentation, and inaccurately stating compliance in audit reports. According to the SEC's order, of 369 BF Borgers' clients whose public filings from January 2021 through June 2023 incorporated the firm's audits and reviews, at least 75 percent of the filings incorporated audits and reviews that did not comply with PCAOB standards. The financials in this report may include past audits and reviews conducted by BF Borgers CPA PC that are deemed not compliant with PCAOB standards.
Business Summary
Adorbs Inc., formerly Soul Biotechnology Corporation, is a holding company. The Company operates through its wholly owned subsidiary, MySpray Therapeutics Inc. (MySpray). MySpray creates clinically developed products for the global natural health community in the areas of immune function, mental health, and pain management. MySpray offers products in a variety of delivery systems, including topical, capsules, and through a highly absorbed convenient oral spray delivery system. Its products include MyShrooms Immune-Pro, MyShrooms Defence, MyShrooms Immunity, MyShrooms Energy and MyPain LiniMint. The Company is preparing to expand formulas to support clinical trials along with the licensing for research and development in the fields of mental health and the impact of treatment protocols with phytonutrients, medicinal mushrooms, and psychedelic compounds under its MyShrooms brand.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202312/31/2022YesYes---

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products
2834 Pharmaceutical preparations
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Company Secretary, Director NicholMartinuik 48 3/13/2023 3/13/2023
President, Treasurer, Secretary & Director Rebecca JillLazar
Chief Executive Officer, Chief Financial Officer, Treasurer, Director RachelMartinuik 48 3/13/2023 3/13/2023

Business Names
Business Name
ADOB
MySpray Therapeutics Inc.

General Information
Number of Employees: 5 (As of 12/31/2022)
Outstanding Shares: 598,545,644 (As of 11/20/2023)
Shareholders: 45
Stock Exchange: OTC
Federal Tax Id: 082315523


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024